CMTTdb

An integrated database for cancer molecular targeted thearpies

Entry Detail


General information
Database:DB00679
Objective:To investigate the safety, optimal dosing, pharmacokinetics and clinical activity of a regimen of navitoclax (ABT263) combined with gemcitabine in patients with solid tumors.
Authors:Cleary JM, et al
Title:a phase I clinical trial of navitoclax, a targeted highaffinity Bcl2 family inhibitor, in combination with gemcitabine in patients with solid tumors.
Journal:Invest New Drugs.
Year:2014
PMID:24916770
Trial Design
Clinical Trial Id:NCT00887757
Agent:navitoclax
Target:Bcl2like protein 2
Antiapoptotic protein BCLXL
Apoptosis regulator Bcl2
Cancer Type:advanced solid tumors
Cancer Subtype:advanced solid tumors
Therapy Type:com
Therapeutic Combination Type:2
Therapeutic Combination Content:navitoclax+gemcitabine
Study Type:Phase I trial
Key Patients Feature:Eligible patients were required to have a histologically documented cancer type for which gemcitabine was considered anappropriate indication therapy by the treating physician.patients were required to have measurable disease as definedby Response Evaluation Criteria In Solid Tumors (RECIST)Version 1.1 [15], Eastern Cooperative Oncology GroupPerformance Status (ECOG PS [16]) less than and equal to 1, and adequate function of the bone marrow (absolute neutrophil count more than and equal to 1, 500/¦ÌL; platelets more than and equal to 150, 000/mm3; hemoglobin more than and equal to 9.0 g/dL), kidney(serum creatinine less than and equal to 2.0 mg/dL or calculated creatinine clearance more than and equal to 50 mL/min), and liver (aspartate aminotransferase[AST], alkaline phosphatase [ALP], and alanine aminotransferase [ALT] less than and equal to 3.0¡Áthe upper limit of normal [ULN]; bilirubinless than and equal to 1.5¡ÁULN). Patients with bone metastasis could have ALPless than and equal to 5.0¡ÁULN; patients with liver metastasis could have AST, ALP, and ALT less than and equal to 5.0¡ÁULN. Coagulation parameters (activatedpartial thromboplastin time and prothrombin time) were required to be below 1.2¡ÁULN
Biomarker:NA
Biomark Analysis:NA
Control Group Info:single arm,
Treatment Info:21day dosing schedule: navitoclax administered orally on days 13 and 810, ; and gemcitabine 1, 000 mg/m(2) on days 1 and 8; 28day dosing schedule: navitoclax administrated orally on days 13, 810, and 1517; and gemcitabine 1, 000 mg/m(2) on days 1, 8 and 15.Navitoclax doses were escalated from 150 to 425 mg. An expanded safety cohort was conducted for the 21day dosing schedule at the maximum tolerated dose (MTD) of navitoclax.
Primary End Point:the safety and maximum tolerated dose (MTD), as well as the pharmacokinetic (PK) interaction.
Secondary End Point:safety at the recommended dose and schedule and preliminary antitumoractivity of the combination.
Patients Number:46
Trial Results
DLT_MTD:Doselimiting toxicities (DLTs) observed in cycle 1 were grade 4 thrombocytopenia (2 patients), grade 4 neutropenia (1 patient), and grade 3 AST elevation (2 patients). The MTD of navitoclax was 325 mg coadministered with gemcitabine 1, 000 mg/m(2) for the 21day schedule.
Objective Response Rate:There were no objective responses. Stable disease, reported at the end of cycle 2, was the best response in 54 % of evaluable patients (n = 39).
Disease Control Rate:NA
Median Time to Progression:NA
Median PFS A vs. C:1.6 months (95 % CI: 1.2, 3.2)
Median OS A vs. C:NA
Adverse Event(agent arm):Treatment related grade 3-4 AEs occurred in 21 patients. Among the AEs of grade 3 and 4 severity observed in more than and equal to 20 % of patients were hematologic abnormalities (thrombocytopenia, neutropenia, leukopenia, or anemia), transaminase elevations, and gastrointestinal disturbances (diarrhea, nausea, or vomiting). The most frequently reported treatmentemergent AEs thought to be attributable to navitoclax were: thrombocytopenia (n=27; 58.7 %), nausea (n=27; 58.7 %), fatigue (n=26;56.5 %), anemia (n=24; 52.2 %), diarrhea (n=21; 45.7 %), vomiting (n=18; 39.1 %), elevated ALT elevation (n=12; 26.1 %), neutropenia (n=12; 26.1 %), decreased appetite (n=12; 26.1 %), elevated AST (n=10; 21.7 %), and leukopenia (n=10; 21.7 %)
Conclusions:The combination of navitoclax 325 mg with gemcitabine 1,000 mg/m(2) was generally well tolerated and exhibited a favorable safety profile in patients with advanced solid tumors.